Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04568395 · ClinicalTrials.gov registry record · NA

Acute Effects of TCIG vs ECIG in PLWH

A NA study of Inflammation and Smoking, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
37
Enrollment target
2
Study locations

NCT04568395: Completed NA study of Inflammation and Smoking, sponsored by University of California, Los Angeles.

NCT04568395 is a NA study of Inflammation and Smoking that has completed, run by University of California, Los Angeles. The registered enrollment target is 37 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04568395, a NA study of Inflammation and Smoking, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target
2
Study locations

Study Summary

Randomized controlled trial of acute use of electronic cigarette or tobacco cigarette on parameters of ventricular repolarization and inflammation/oxidative stress.

Primary Outcome

interval indicative of ventricular repolarization measured on ECG

Interventions

  • OTHER TCIG
  • OTHER ECIG
  • OTHER sham control

Study Locations (2)

California

  • UCLA - Los Angeles
  • UCaliforniaLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2020-10-01
Est. Completion 2023-05-08
Phase NA

What the finished NCT04568395 record still lists

NCT04568395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (87% lower).

The record links to 9 conditions, with Inflammation appearing as the primary indexed condition, and to 3 interventions - of which TCIG is the first listed.

NCT04568395 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04568395 about?

NCT04568395 is a clinical study titled "Acute Effects of TCIG vs ECIG in PLWH". Randomized controlled trial of acute use of electronic cigarette or tobacco cigarette on parameters of ventricular repolarization and inflammation/oxidative stress.

What is the current status of trial NCT04568395?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2020-10-01. Estimated completion is 2023-05-08.

What conditions does trial NCT04568395 study?

This clinical trial studies the following conditions: Inflammation, Smoking, Tobacco Smoking, Oxidative Stress, Vaping.

What interventions are being tested in trial NCT04568395?

The interventions under investigation include: TCIG (OTHER), ECIG (OTHER), sham control (OTHER).

Who is sponsoring clinical trial NCT04568395?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04568395 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04568395's enrollment target sits among peer trials

37 89th of 132 higher than 43 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04568395, the US trial registry maintained by the National Library of Medicine. NCT04568395 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.